Gavi supports vaccines against 20 infectious diseases, including COVID-19, Ebola, malaria and rabies. Learn more about our support for each vaccine by clicking below.
Gavi supports vaccines against 20 infectious diseases, including COVID-19, Ebola, malaria and rabies. Learn more about our support for each vaccine by clicking below.
Gavi-supported introductions into routine immunisation programmes and campaigns with meningococcal A vaccine have reached more than 395 million people, in addition to those reached through the Gavi-funded multivalent meningococcal vaccine stockpile for outbreak response.
Gavi-supported introductions into routine immunisation programmes and campaigns with meningococcal A vaccine have reached more than 395 million people, in addition to those reached through the Gavi-funded multivalent meningococcal vaccine stockpile for outbreak response.
Gavi helps to prevent cholera outbreaks and control endemic cholera through its support to the Global Oral Cholera Vaccine (OCV) Stockpile and preventive OCV programme.
Gavi helps to prevent cholera outbreaks and control endemic cholera through its support to the Global Oral Cholera Vaccine (OCV) Stockpile and preventive OCV programme.
The funding window for rabies post-exposure prophylaxis (PEP) vaccine will open in June 2024, when detailed guidelines will be posted on the Gavi Support Guidelines webpage. Read VaccinesWork articles related to rabies.
The funding window for rabies post-exposure prophylaxis (PEP) vaccine will open in June 2024, when detailed guidelines will be posted on the Gavi Support Guidelines webpage. Read VaccinesWork articles related to rabies.
Gavi supports countries to introduce and roll out the rotavirus vaccine, protecting against severe and deadly diarrhoea that killed ~370,000 children globally in 2019.
Gavi supports countries to introduce and roll out the rotavirus vaccine, protecting against severe and deadly diarrhoea that killed ~370,000 children globally in 2019.
Gavi funding for the new typhoid conjugate vaccine (TCV), which protects against typhoid fever and can curb antimicrobial resistance, became available in 2018.
Gavi funding for the new typhoid conjugate vaccine (TCV), which protects against typhoid fever and can curb antimicrobial resistance, became available in 2018.
Gavi provides yellow fever vaccine support for its introduction into routine immunisation programmes, as well as funding for campaigns in high-risk countries and an emergency stockpile in case of outbreaks.
Gavi provides yellow fever vaccine support for its introduction into routine immunisation programmes, as well as funding for campaigns in high-risk countries and an emergency stockpile in case of outbreaks.